<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254475</url>
  </required_header>
  <id_info>
    <org_study_id>CVAS489A2403</org_study_id>
    <nct_id>NCT00254475</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia</brief_title>
  <official_title>A Study to Evaluate the Efficacy of the Valsartan/Simvastatin Combinations 160/20mg up Titrated to 320/20mg Versus 160/40mg up Titrated to 320/40mg in Patients With Both Essential Hypertension and Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide data on the dose response of simvastatin in lowering
      LDL-C when it is co-administered with valsartan in patients with both essential hypertension
      and hypercholesterolemia. The primary objective of the study will be to show that the
      combination of valsartan 160mg/simvastatin 40mg has superior efficacy compared to the
      combination of valsartan 160mg/simvastatin 20mg in percentage change from baseline in LDL-C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoproteins after 6 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile at 6, 12 wks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP &lt; 140/90 mmHg in non diabetics, or &lt; 130/80 mmHg in diabetics, and LDL-C &lt; 2.6, 3.4 or 4.1 mmol/l based on risk group at 6, 12 wks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP &lt; 140 mmHg in non diabetics, &lt; 130 mmHg in diabetics, or 20 mmHg decrease in SBP from baseline and DBP &lt; 90 mmHg in non diabetics, DBP &lt; 80 mmHg in diabetics, or 10 mmHg decrease in DBP from baseline at 6, 12 wks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic bp at 6, 12 wks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious/adverse events, labs, physical exams, vitals up to 12 wks</measure>
  </secondary_outcome>
  <enrollment type="Actual">871</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated LDL-Cholesterol

          -  Essential hypertension

        Exclusion Criteria:

          -  Severe Hypertension

          -  Prior or known muscular or neuromuscular disease of any type

          -  A history of cardiovascular disease

          -  Hypertension or hypercholesterolemia due to secondary causes

          -  Uncontrolled diabetes or insulin treatment

          -  Evidence of hepatic or renal disease

        Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceutical</last_name>
    <role>Study Director</role>
    <affiliation>Novatis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2005</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valsartan</keyword>
  <keyword>simvastatin</keyword>
  <keyword>hypertension</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>angiotensin II receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

